source
- Vertex awaits FDA decision on povetacicept for IgA nephropathy, analysts expect approvalVertex Pharmaceuticals is awaiting an FDA ruling this month on its investigational drug povetacicept, being evaluated for the treatment of IgA nephropathy. Analysts, including Myles Minter of Will…
- Sellas cancer vaccine cuts death risk by 41% in late-stage AML trialSellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…